{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:10:33Z","timestamp":1794564633757,"version":"4.9.1"},"reference-count":55,"publisher":"American Society of Hematology","issue":"11","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,3,18]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic myeloid leukemia (CML) is treated effectively with tyrosine kinase inhibitors (TKIs); however, 2 key problems remain\u2014the insensitivity of CML stem and progenitor cells to TKIs and the emergence of TKI-resistant BCR-ABL mutations. BCR-ABL activity is associated with increased proteasome activity and proteasome inhibitors (PIs) are cytotoxic against CML cell lines. We demonstrate that bortezomib is antiproliferative and induces apoptosis in chronic phase (CP) CD34+ CML cells at clinically achievable concentrations. We also show that bortezomib targets primitive CML cells, with effects on CD34+38\u2212, long-term culture-initiating (LTC-IC) and nonobese diabetic\/severe combined immunodeficient (NOD\/SCID) repopulating cells. Bortezomib is not selective for CML cells and induces apoptosis in normal CD34+38\u2212 cells. The effects against CML cells are seen when bortezomib is used alone and in combination with dasatinib. Bortezomib causes proteasome but not BCR-ABL inhibition and is also effective in inhibiting proteasome activity and inducing apoptosis in cell lines expressing BCR-ABL mutations, including T315I. By targeting both TKI-insensitive stem and progenitor cells and TKI-resistant BCR-ABL mutations, we believe that bortezomib offers a potential therapeutic option in CML. Because of known toxicities, including myelosuppression, the likely initial clinical application of bortezomib in CML would be in resistant and advanced disease.<\/jats:p>","DOI":"10.1182\/blood-2008-06-164582","type":"journal-article","created":{"date-parts":[[2010,1,13]],"date-time":"2010-01-13T04:44:55Z","timestamp":1263357895000},"page":"2241-2250","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":46,"title":["Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD\/SCID repopulating cells"],"prefix":"10.1182","volume":"115","author":[{"given":"Nicholas B.","family":"Heaney","sequence":"first","affiliation":[{"name":"Paul O'Gorman Leukaemia Research Centre, Medical Faculty, University of Glasgow, Glasgow, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Pellicano","sequence":"additional","affiliation":[{"name":"Paul O'Gorman Leukaemia Research Centre, Medical Faculty, University of Glasgow, Glasgow, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Leukemia Research, Division of Population Sciences, City of Hope National Medical Centre, Duarte, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Crawford","sequence":"additional","affiliation":[{"name":"Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Chu","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Leukemia Research, Division of Population Sciences, City of Hope National Medical Centre, Duarte, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed M. A.","family":"Kazmi","sequence":"additional","affiliation":[{"name":"Paul O'Gorman Leukaemia Research Centre, Medical Faculty, University of Glasgow, Glasgow, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine K.","family":"Allan","sequence":"additional","affiliation":[{"name":"Paul O'Gorman Leukaemia Research Centre, Medical Faculty, University of Glasgow, Glasgow, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather G.","family":"Jorgensen","sequence":"additional","affiliation":[{"name":"Paul O'Gorman Leukaemia Research Centre, Medical Faculty, University of Glasgow, Glasgow, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra E.","family":"Irvine","sequence":"additional","affiliation":[{"name":"Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Department of Stem Cell and Leukemia Research, Division of Population Sciences, City of Hope National Medical Centre, Duarte, CA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa L.","family":"Holyoake","sequence":"additional","affiliation":[{"name":"Paul O'Gorman Leukaemia Research Centre, Medical Faculty, University of Glasgow, Glasgow, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"4944","key":"2019111723092578500_B1","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome.","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"issue":"8","key":"2019111723092578500_B2","first-page":"1735","article-title":"Activation of the Abelson tyrosine kinase activity is associated with suppression of apoptosis in hemopoietic cells.","volume":"53","author":"Evans","year":"1993","journal-title":"Cancer Res"},{"issue":"6","key":"2019111723092578500_B3","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111723092578500_B4","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"issue":"23","key":"2019111723092578500_B5","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111723092578500_B6","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1182\/blood-2004-04-1335","article-title":"Discontinuation of imatinib therapy after achieving a molecular response.","volume":"104","author":"Cortes","year":"2004","journal-title":"Blood"},{"issue":"12","key":"2019111723092578500_B7","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2002-09-2780","article-title":"Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment.","volume":"101","author":"Bhatia","year":"2003","journal-title":"Blood"},{"issue":"11","key":"2019111723092578500_B8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V112.11.194.194","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib treatment for 5 years.","volume":"112","author":"Chu","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111723092578500_B9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"issue":"6","key":"2019111723092578500_B10","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1182\/blood.V94.6.2056","article-title":"Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia.","volume":"94","author":"Holyoake","year":"1999","journal-title":"Blood"},{"issue":"9","key":"2019111723092578500_B11","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1182\/blood.V98.9.2808","article-title":"Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.","volume":"98","author":"Wolff","year":"2001","journal-title":"Blood"},{"issue":"2","key":"2019111723092578500_B12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia.","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"issue":"5531","key":"2019111723092578500_B13","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"issue":"6","key":"2019111723092578500_B14","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2019111723092578500_B15","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib.","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111723092578500_B16","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1182\/blood-2007-04-083196","article-title":"Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.","volume":"111","author":"le Coutre","year":"2008","journal-title":"Blood"},{"issue":"6","key":"2019111723092578500_B17","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/leu.2008.84","article-title":"Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.","volume":"22","author":"Hochhaus","year":"2008","journal-title":"Leukemia"},{"issue":"11","key":"2019111723092578500_B18","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction.","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111723092578500_B19","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1182\/blood-2007-05-092056","article-title":"Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src\/Abl kinase inhibitor SKI-606.","volume":"111","author":"Konig","year":"2008","journal-title":"Blood"},{"issue":"9","key":"2019111723092578500_B20","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells.","volume":"109","author":"J\u00f8rgensen","year":"2007","journal-title":"Blood"},{"issue":"18","key":"2019111723092578500_B21","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1073\/pnas.87.18.7071","article-title":"Abnormally high expression of proteasomes in human leukemic cells.","volume":"87","author":"Kumatori","year":"1990","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2019111723092578500_B22","first-page":"1428","article-title":"Proteasome proteolytic activity in hematopoietic cells from patients with chronic myeloid leukemia and multiple myeloma.","volume":"89","author":"Magill","year":"2004","journal-title":"Haematologica"},{"issue":"11","key":"2019111723092578500_B23","first-page":"2615","article-title":"Proteasome inhibitors: a novel class of potent and effective antitumor agents.","volume":"59","author":"Adams","year":"1999","journal-title":"Cancer Res"},{"issue":"10","key":"2019111723092578500_B24","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-03-0508","article-title":"Phase I study of bortezomib in refractory or relapsed acute leukemias.","volume":"10","author":"Cortes","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111723092578500_B25","first-page":"2505","article-title":"A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies.","volume":"8","author":"Aghajanian","year":"2002","journal-title":"Clin Cancer Res"},{"issue":"25","key":"2019111723092578500_B26","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1200\/JCO.2005.01.136","article-title":"Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle.","volume":"23","author":"Hamilton","year":"2005","journal-title":"J Clin Oncol"},{"issue":"22","key":"2019111723092578500_B27","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1200\/JCO.2002.01.133","article-title":"Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.","volume":"20","author":"Orlowski","year":"2002","journal-title":"J Clin Oncol"},{"issue":"11","key":"2019111723092578500_B28","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1200\/JCO.2004.02.106","article-title":"Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.","volume":"22","author":"Papandreou","year":"2004","journal-title":"J Clin Oncol"},{"issue":"7","key":"2019111723092578500_B29","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1101\/gad.12.7.968","article-title":"A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation.","volume":"12","author":"Reuther","year":"1998","journal-title":"Genes Dev"},{"issue":"6","key":"2019111723092578500_B30","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0301-472X(03)00069-9","article-title":"Mechanisms of Bcr-Abl-mediated NF-kappaB\/Rel activation.","volume":"31","author":"Kirchner","year":"2003","journal-title":"Exp Hematol"},{"issue":"2","key":"2019111723092578500_B31","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.cell.2006.11.047","article-title":"Cdk-inhibitory activity and stability of p27Kip1 are directly regulated by oncogenic tyrosine kinases.","volume":"128","author":"Grimmler","year":"2007","journal-title":"Cell"},{"issue":"8","key":"2019111723092578500_B32","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1158\/0008-5472.CAN-04-1357","article-title":"BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.","volume":"65","author":"Andreu","year":"2005","journal-title":"Cancer Res"},{"issue":"9","key":"2019111723092578500_B33","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/sj.onc.1210744","article-title":"BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.","volume":"27","author":"Fennell","year":"2008","journal-title":"Oncogene"},{"issue":"43","key":"2019111723092578500_B34","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1038\/sj.onc.1206792","article-title":"Phosphorylation of Bim-EL by Erk1\/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function.","volume":"22","author":"Luciano","year":"2003","journal-title":"Oncogene"},{"issue":"14","key":"2019111723092578500_B35","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1128\/MCB.24.14.6172-6183.2004","article-title":"Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors.","volume":"24","author":"Kuribara","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"20","key":"2019111723092578500_B36","doi-asserted-by":"crossref","first-page":"9436","DOI":"10.1158\/0008-5472.CAN-05-0972","article-title":"Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR\/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.","volume":"65","author":"Aichberger","year":"2005","journal-title":"Cancer Res"},{"issue":"40","key":"2019111723092578500_B37","doi-asserted-by":"crossref","first-page":"14907","DOI":"10.1073\/pnas.0606176103","article-title":"Bim and Bad mediate imatinib-induced killing of Bcr\/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.","volume":"103","author":"Kuroda","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"2019111723092578500_B38","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.leukres.2006.01.005","article-title":"Adaphostin and bortezomib induce oxidative injury and apoptosis in imatinib mesylate-resistant hematopoietic cells expressing mutant forms of Bcr\/Abl.","volume":"30","author":"Dasmahapatra","year":"2006","journal-title":"Leuk Res"},{"issue":"8","key":"2019111723092578500_B39","first-page":"853","article-title":"The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr\/Abl-positive cell lines sensitive and resistant to imatinib mesylate.","volume":"88","author":"Gatto","year":"2003","journal-title":"Haematologica"},{"issue":"7","key":"2019111723092578500_B40","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/sj.leu.2404735","article-title":"Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase C delta.","volume":"21","author":"Yan","year":"2007","journal-title":"Leukemia"},{"issue":"12","key":"2019111723092578500_B41","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/sj.leu.2403987","article-title":"Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I.","volume":"19","author":"Servida","year":"2005","journal-title":"Leukemia"},{"issue":"11","key":"2019111723092578500_B42","first-page":"4971","article-title":"Phase II study of bortezomib (VELCADE, formerly PS-341) for patients with imatinib-refractory chronic myeloid leukemia (CML) in chronic (CP) or accelerated phase (AP).","volume":"102","author":"Cortes","year":"2003","journal-title":"Blood"},{"key":"2019111723092578500_B43","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"issue":"5","key":"2019111723092578500_B44","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood-2007-09-112573","article-title":"BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.","volume":"111","author":"Copland","year":"2008","journal-title":"Blood"},{"issue":"23","key":"2019111723092578500_B45","doi-asserted-by":"crossref","first-page":"9624","DOI":"10.1158\/0008-5472.CAN-08-1131","article-title":"Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.","volume":"68","author":"Konig","year":"2008","journal-title":"Cancer Res"},{"issue":"14","key":"2019111723092578500_B46","doi-asserted-by":"crossref","first-page":"8081","DOI":"10.1073\/pnas.95.14.8081","article-title":"Evidence for a role of NF-kappaB in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL\/platelet-derived growth factor receptor beta fusion protein.","volume":"95","author":"Besan\u00e7con","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2019111723092578500_B47","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"issue":"7","key":"2019111723092578500_B48","first-page":"3071","article-title":"The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.","volume":"61","author":"Hideshima","year":"2001","journal-title":"Cancer Res"},{"issue":"6","key":"2019111723092578500_B49","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/j.1365-2141.2007.06504.x","article-title":"The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells.","volume":"136","author":"Stapnes","year":"2007","journal-title":"Br J Haematol"},{"issue":"11","key":"2019111723092578500_B50","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood.V108.11.3533.3533","article-title":"Pharmacokinetic (PK) and pharmacodynamics (PD) study of two doses of bortezomib (Btz) in patients with relapsed multiple myeloma (MM).","volume":"108","author":"Stewart","year":"2006","journal-title":"Blood"},{"issue":"8","key":"2019111723092578500_B51","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1182\/blood.V98.8.2301","article-title":"Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells.","volume":"98","author":"Guzman","year":"2001","journal-title":"Blood"},{"issue":"1","key":"2019111723092578500_B52","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3324\/haematol.11666","article-title":"The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.","volume":"93","author":"Colado","year":"2008","journal-title":"Haematologica"},{"issue":"9","key":"2019111723092578500_B53","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1158\/1078-0432.CCR-04-2068","article-title":"A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.","volume":"11","author":"Dy","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2019111723092578500_B54","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2019111723092578500_B55","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood.V112.11.1103.1103","article-title":"Homo-harringtonine (omacetaxine mepesuccinate) induces a dramatic and sustained reduction of BCR-ABL T315I mutated transcripts in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors.","volume":"112","author":"Nicolini","year":"2008","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/115\/11\/2241\/1323720\/zh801110002241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/115\/11\/2241\/1323720\/zh801110002241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T18:00:30Z","timestamp":1590516030000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/115\/11\/2241\/27050\/Bortezomib-induces-apoptosis-in-primitive-chronic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,18]]},"references-count":55,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2010,3,18]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-06-164582","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,18]]}}}